Skip to content

Author

Vivek Phatale

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Unlocking exosome potential: Comprehensive review on diagnostic, prognostic and therapeutic approaches in melanoma.

Melanoma is one of the most lethal and aggressive forms of skin malignancies, which characterized by a high mutational burden, rapid metastatic dissemination and development of resistance to targeted and conventional therapies. Increasing interest in site-specific delivery has led to tailored therapeutic delivery mechanisms, resulting in enhanced pharmacodynamic success and diminished adverse effects. Currently, melanoma is marked by multifaceted mechanisms that interplay with drug resistance and enhanced metastatic propensity, providing a paradigm for exosome-mediated delivery. The advent of engineered exosomes poses an innovative delivery platform that transports diverse bioactive cargo such as DNA, lipids, proteins and mRNA, thereby modulating immune evasion, angiogenesis, pre-metastatic niche formation, tumor progression and therapeutic resistance. Beyond their biological functions, exosomes have emerged as potential minimally invasive biomarkers for melanoma prognosis, diagnosis and treatment monitoring owing to their biocompatibility, stability and capability to imitate the molecular profile of the primary tumor. The current developments in exosome engineering have marked their potential as natural nanocarriers in various therapeutic delivery approaches like chemotherapy, immunotherapy, radiotherapy and codelivery. The current review highlights the promising potential of exosome-based therapeutics as targeted therapeutics, prognostic and diagnostic biomarkers, and as a theranostic platform. Furthermore, the review critically analyzes current challenges associated with isolation and characterization of exosomes, safety, reproducibility, large-scale manufacturing and regulatory considerations of exosome-based therapeutics. Collectively, exosome-based strategies hold substantial potential for improving the diagnosis and management of melanoma, which may encourage the development of next-generation therapeutic interventions in the medical world.

Aashi Srivastava, Pooja Khairnar, Pallavi Chaure et al. · 0 citations
Aug 2026

Intranasal Pacritinib-loaded nanoemulsion for Glioblastoma management: In Vitro, ex Vivo, 3D spheroid and In vivo brain biodistribution studies.

Pacritinib (PAC), a potent inhibitor of JAK2, is currently being explored as a potential therapeutic agent against GBM, which is an aggressive and vascularized brain tumor, resistant to many therapies. The therapeutic potential of PAC is hindered due to its poor water solubility and low brain bioavailability. In the current study, a PAC-loaded nanoemulsion (PAC-NE) was formulated to deliver the drug through the intranasal (IN) route for better solubilization, nasal absorption, and brain targeting. The optimized formulation of PAC-NE exhibited a mean droplet size of 18.78 ± 0.4 nm and a polydispersity index (PDI) value of 0.183 ± 0.007, representing a highly homogenous and uniform NE, which is appropriate for nasal administration. In vitro evaluation of the anticancer efficacy in 2D cell culture and 3D tumor spheroid model (3DS) proved that PAC-NE greatly improved the cellular uptake, cytotoxicity, and tumor spheroid inhibition activity compared with free PAC. In addition, ex vivo nasal permeation was greatly improved by the optimized formulation, showing a flux value of 1.27 ± 0.06 µg/cm2/h and a permeability coefficient value of 2.4 × 10⁻7 ± 0.19 cm/s, which were significantly higher than that of the plain drug. Moreover, the histopathological examination demonstrated no sign of damage to the nasal mucosa. Pharmacokinetics analysis following IN application revealed that the optimized NE depicted greater brain-targeting ability, where there was an improvement in %DTE by 1.99-fold and in %DTP by 2.75-fold in comparison to free PAC. Overall, from the above observations, it can be concluded that PAC-NE is a non-invasive delivery system which shows promising results for better brain delivery thereby supporting the clinical translation of PAC for GBM therapy.

Anupama Sikder, Shraddha Naresh Katarpawar, Vivek Phatale et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.